Citations

Clear

118 citation(s) found for "Bower, James".

Infections or Sepsis Preceding Clinically Diagnosed α‐Synucleinopathies: A Case‐Control Study
Hasan, Shemonti , Ahlskog, J. Eric , Bower, James H., Turcano, Pierpaolo , Savica, Rodolfo , Savica, Rodolfo , Mielke, Michelle M.

Mayo Clinic

Movement Disorders | June 1, 2020 | Volume: 35 | Issue: 9 | Pages: 1684-1689

10.1002/mds.28111 | PMID 32479692 Get It

AbstractBackgroundSeveral studies have proposed a role for infections to induce an inflammatory response triggering Parkinson's disease. This remains controversial and the influence of severe infections on other α‐synucleinopathies (Dementia with Lewy Bodies, Parkinson's disease dementia, and Multiple System Atrophy) has not been adequately investigated.ObjectivesTo assess the association between hospitalization‐required infections or sepsis and risk of clinically diagnosed α‐synucleinopathies.MethodsUsing the medical records‐linkage system (Rochester Epidemiology Project), we identified all α‐synucleinopathy cases of in Olmsted County (1991–2010). Cases were matched by symptom‐onset age and sex to controls. We reviewed complete medical records to detect hospital‐required infections or sepsis preceding clinical‐motor onset of α‐synucleinopathies. We used conditional logistic regression to calculate the odds ratio of all α‐synucleinopathies, adjusting for medications, coffee, and smoking.ResultsThere was no association between infection‐related hospitalization (odds ratio: 1.05; 95% confidence interval: 0.78–1.40; P = 0.76) or sepsis (odds ratio: 0.86; 95% confidence interval: 0.40–1.85; P = 0.70) and all α‐synucleinopathies in multivariable analyses. We did not identify any associations after stratifying for type of α‐synucleinopathy, sex, and age at clinical‐motor onset. We analyzed sepsis separately with similar results.ConclusionWe did not observe any associations between infections leading to hospitalization or sepsis and development of any α‐synucleinopathies. © 2020 International Parkinson and Movement Disorder Society
Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival
McCarter, Stuart J. , Savica, Rodolfo , Louis, Erik K. St. , Bower, James H., Benarroch, Eduardo E. , Sandroni, Paola , Low, Phillip A. , Savica, Rodolfo , St Louis, E K , McCarter, Stuart J , Coon, Elizabeth A. , Singer, Wolfgang

Mayo Clinic

Movement Disorders | April 22, 2020 | Volume: 35 | Issue: 8 | Pages: 1462-1466

10.1002/mds.28070 | PMID 32320519 Get It

Abstract Background Multiple system atrophy (MSA) is a neurodegenerative disorder from α‐synuclein aggregation. in vitro studies suggest vitamin B12 may interrupt α‐synuclein‐mediated neurodegeneration. The objective of this study was to determine whether serum vitamin B12 level at MSA diagnosis is associated with survival. Methods One hundred eighty‐two MSA patients evaluated at Mayo Clinic with vitamin B12 testing were studied. We determined the risk of death in relationship to serum vitamin B12 levels at MSA diagnosis, adjusting for predictors of poor survival. Results Predictors of shorter survival included vitamin B12 < 367 ng/L (HR, 1.8; 95% CI, 1.3–2.7), falls within 3 years of MSA diagnosis (HR, 1.6; 95% CI, 1.1–2.3), bladder symptoms (HR, 1.6; 95% CI, 1.0–2.6), urinary catheter requirement (HR, 1.7; 95% CI, 1.0–2.8), male sex (HR, 1.4; 95% CI, 1.0–2.0), and MSA‐P subtype (HR, 1.5; 95% CI, 1.0–2.0). Conclusions Low vitamin B12 levels are associated with shorter survival in MSA. Additional studies to explore this observation and assess the potential role of vitamin B12 as a modifiable survival factor are needed. © 2020 International Parkinson and Movement Disorder Society
Traumatic brain injury preceding clinically diagnosed α-synucleinopathies
Hasan, Shemonti , Turcano, Pierpaolo , Ahlskog, J. Eric , Bower, James H., Savica, Rodolfo , Savica, Rodolfo , Mielke, Michelle M.

Mayo Clinic

Neurology | January 29, 2020 | Volume: 94 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000008995 | PMID 31992680 Get It

Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia
Turcano, Pierpaolo , Stang, Cole , Bower, James H., Ahlskog, J. Eric , Savica, Rodolfo , Stang, Cole D., Boeve, Bradley F. , Mielke, Michelle M.

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 2 | Pages: 156-161

10.1212/cpj.0000000000000703 | PMID 32309034 Get It

Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia
Butterfield, JH, Leiferman, KM, Abrams, J S, Silver, JE, Bower, James H., Gonchoroff, Nick J., Gleich, GJ

Mayo Clinic

Blood | October 13, 2019 | Volume: 79 | Issue: 3 | Pages: 688-692

10.1182/blood.v79.3.688.688 Get It

Abstract The syndrome of episodic angioedema and eosinophilia is characterized by cyclic edema, marked peripheral blood eosinophilia, and eosinophil degranulation in the dermis. Using a sensitive immunoenzymetric method, we measured serum interleukin (IL)-5 levels in four patients with this syndrome. We also determined the percentage of activated T cells in the peripheral blood of a new patient before and during an attack. In the patient presented, IL-5 levels peaked several days before maximal eosinophilia and then declined. This patient's lymphocytes showed an increased percentage, 28% (normal 2% to 3%), of activated T cells staining for both CD3 and HLA-DR 10 days before maximal eosinophilia, but no increase at the time of peak eosinophilia. In serum from three previously reported cases, elevated serum IL-5 levels were found during attacks. After glucocorticoid administration, IL-5 levels became undetectable in three of the four patients. Production of IL-5 is likely an important determinant of the pathophysiology of this syndrome.
Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia
Butterfield, JH, Leiferman, KM, Abrams, J S, Silver, JE, Bower, James H., Gonchoroff, Nick J., Gleich, GJ

Mayo Clinic

Blood | October 13, 2019 | Volume: 79 | Issue: 3 | Pages: 688-692

10.1182/blood.v79.3.688.bloodjournal793688 Get It

The syndrome of episodic angioedema and eosinophilia is characterized by cyclic edema, marked peripheral blood eosinophilia, and eosinophil degranulation in the dermis. Using a sensitive immunoenzymetric method, we measured serum interleukin (IL)-5 levels in four patients with this syndrome. We also determined the percentage of activated T cells in the peripheral blood of a new patient before and during an attack. In the patient presented, IL-5 levels peaked several days before maximal eosinophilia and then declined. This patient's lymphocytes showed an increased percentage, 28% (normal 2% to 3%), of activated T cells staining for both CD3 and HLA-DR 10 days before maximal eosinophilia, but no increase at the time of peak eosinophilia. In serum from three previously reported cases, elevated serum IL-5 levels were found during attacks. After glucocorticoid administration, IL-5 levels became undetectable in three of the four patients. Production of IL-5 is likely an important determinant of the pathophysiology of this syndrome.
Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study
Stang, Cole , Turcano, Pierpaolo , Josephs, Keith A. , Bower, James H., Ahlskog, J. Eric , Martin, Peter R. , Upadhyaya, Sudhindra, Savica, Rodolfo , Stang, Cole D., Upadhyaya, Sudhindra G, Mielke, Michelle M. , Boeve, Bradley F.

Mayo Clinic

Journal of Parkinson’s Disease | October 1, 2019 | Volume: 10 | Issue: 1 | Pages: 179-184

10.3233/jpd-191744 | PMID 31594251 Get It

Background: Few studies have investigated the incidence of PSP and CBS in the population. Objective: To examine the incidence of and trends in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) in a population-based cohort of residents of Olmsted County, MN. Methods: We used the 1991-2005 population-based, Olmsted County Parkinsonism-cohort study, defined via the Rochester Epidemiology Project. A movement-disorder specialist reviewed medical records, to confirm PSP and CBS diagnoses. Results: We identified 21 patients with these diagnoses 1991-2005 : 18 (85.7%), PSP; 3 (14.3%), CBS. The median diagnosis age was 78 (range: 66-88). 13/21 (62.0%) were male. MRI was performed pre-diagnosis in 11 patients (8 PSP and 3 CBD); 10 showed atrophy consistent with clinical diagnoses. We observed concordance between clinical and pathological diagnoses in two PSP patients who underwent autopsy. Combined incidence for PSP and CBS in Olmsted County was 3.1 per 100,000 person-years (2.6 per 100,000 person-years, PSP; 0.4 per 100,000 person-years, CBS). Incidence was higher in men (4.5, 95% CI, 2.0-7.0) than women (1.8, 95% CI, 0.5-2.9). A combined, significant trend of increasing incidence was observed between 1991 and 2005 (B=0.69, 95% CI 0.42, 0.96, p<0.001). Median time from symptom onset to death among both groups was 6 years (range PSP, 1-10 years; range CBS, 3-8 years). Conclusions: The combined incidence for PSP and CBS was 3.1 per 100,000 person-years, higher in men than women. We observed a significant increase in both PSP and CBS, likely due to advancing imaging technology and improved diagnostic ability among physicians.
Prevalence of sleep disorders in Parkinson’s disease patients in two Neurology referral hospitals in Ethiopia
Melka, Dereje , Tafesse, Abenet , Bower, James H., Assefa, Demeke

Mayo Clinic

No container title available | July 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.442/v3 Get It

Abstract Background: Non motor symptoms (NMS) of Parkinson’s disease (PD) are common and can be more disabling than motor symptoms.Sleep disorders can be seen in up to 98% of patients with Parkinson disease. Poor sleep quality has been associated with poverty and race, and yet there has been no prior report on sleep disorders in those with PD living in sub Saharan Africa. We wished to document the prevalence of sleep disorders in PD patients in Ethiopia. Methods: We conducted a cross-sectional point prevalence study from July 1 to October 30, 2015 of all patients attending the neurology outpatient department in Tikur Anbessa and Zewuditu Memorial Hospitals, Addis Ababa, Ethiopia. Demographic data, clinical history and physical examination findings were collected from participants using a structured questionnaire. We used the Parkinson’s disease sleep scale version two (PDSS-2) and Epworth Sleepiness Scale (ESS) to assess the sleep symptoms. Results: Of the 155 patients surveyed, all patients reported some sleep problem. Over 43.9% of patients had a PDSS score > 18. The median score of ESS was 9 (IQR = 5-12), with 77/155 (49.7%) of the patients having possible or definite excessive daytime somnolence. A high EDSS score significantly associated with a Hoehn & Yahr score > 4 (p= 0.02). Conclusions: In Ethiopian PD patients, the prevalence of those with severe sleep disorders is the highest reported to date. The prevalence of possible/definite EDS is amongst the highest in the world. Further investigation into whether poverty or race explains this finding is needed.
Erectile Dysfunction Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study in Olmsted County
Hasan, Shemonti , Mielke, Michelle M. , Ahlskog, J. Eric , Bower, James H., Turcano, Pierpaolo , Savica, Rodolfo , Mielke, Michelle M

Mayo Clinic

Parkinson's Disease | April 9, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-6

10.1155/2019/6303945 | PMID 31093326 Get It

Objective. Autonomic symptoms are common in α-synuclein disorders: multiple system atrophy (MSA), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and Parkinson’s disease with dementia (PDD). These symptoms may precede the motor findings/clinical diagnosis by years. Erectile dysfunction (ED) is an autonomic symptom that has rarely been studied in these α-synuclein disorders. In this population-based, case-control study, we investigated the association between premonitory erectile dysfunction surfacing prior to the clinical-motor manifestations of these α-synucleinopathies. Methods. We used the medical record-linkage system of the Rochester Epidemiology Project to identify cases of α-synucleinopathies in Olmsted County from 1991 to 2010. Each male case was matched by age (±1 year) of symptom onset and sex to a control. We reviewed complete medical records of cases and controls to detect erectile dysfunction prior to the clinical-motor onset of α-synucleinopathies of any type. We used conditional logistic regression to calculate the odds ratio of all α-synucleinopathies, as well as by type, adjusting for diabetes, coffee, and smoking. Results. A history of male erectile dysfunction was associated with 1.5-fold increased odds of an α-synucleinopathy diagnosis of any type in univariate analyses (p=0.06). When stratifying α-synucleinopathies by type, early erectile dysfunction was most frequent in MSA cases than matched controls (45% vs. 9%). Premotor phase ED was next most frequent among the DLB cases (46% vs. 27% among the controls; OR = 2.83, p=0.03; when adjusted for diabetes, smoking, and coffee, OR = 2.98, p=0.04). Premotor phase ED was not significantly associated with PD or PDD. Conclusions. Early erectile dysfunction may be a premotor symptom of MSA and DLB, reflecting premonitory dysautonomia. It was not associated with premotor PD or PDD.